Jeanmarie Guenot
Direttore/Membro del Consiglio presso Pathios Therapeutics Ltd.
Profilo
Jeanmarie Guenot is the founder of Harpoon Therapeutics, Inc. founded in 2015.
She is also the founder of Amphivena Therapeutics, Inc. Dr. Guenot's current job is Non-Executive Director at Pathios Therapeutics Ltd.
where she started in 2022.
Dr. Guenot's former jobs include Scientist-Research & Development at Hoffmann-La Roche, Inc. and Vice President-Corporate & Business Development at PDL BioPharma, Inc. Dr. Guenot holds an MBA from the University of Pennsylvania and a doctorate from The University of California, San Francisco.
Posizioni attive di Jeanmarie Guenot
Società | Posizione | Inizio |
---|---|---|
Pathios Therapeutics Ltd.
Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | 30/11/2022 |
Precedenti posizioni note di Jeanmarie Guenot
Società | Posizione | Fine |
---|---|---|
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Amministratore Delegato | 03/12/2019 |
HARPOON THERAPEUTICS, INC. | Fondatore | - |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Direttore Tecnico/Scientifico/R&S | - |
PDL BIOPHARMA, INC. | Corporate Officer/Principal | - |
Formazione di Jeanmarie Guenot
The University of California, San Francisco | Doctorate Degree |
University of Pennsylvania | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
HARPOON THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Pathios Therapeutics Ltd.
Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Jeanmarie Guenot